$120.39
3.593.07%
Last update: Oct 30, 4:02 PM
Incyte Corp (INCY) Stock Price, Quote, News & History
INCYNASDAQ
Genmab shares positive petosemtamab trial data across multiple solid tumors at ESMO and partners with Incyte on targeted colorectal therapy.
You can purchase shares of Incyte (NASDAQ:INCY) through any online brokerage.
Other companies in Incyte’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Incyte has a consensus price target of $121.96.
The stock price for Incyte (NASDAQ: INCY) is $120.41 last updated October 30, 2026 at 4:02 PM EDT.
There are no upcoming dividends for Incyte.
Incyte does not have any upcoming earnings scheduled.
There is no upcoming split for Incyte.
Incyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include...
